SERDA Therapeutics focuses on innovative solutions for the therapeutic debridement of burn injuries and chronic wounds, such as diabetic foot ulcers and open leg wounds. These types of wounds often present significant challenges for both patients and healthcare providers, primarily due to the presence of eschar and necrotic tissue that impede the healing process. Traditional debridement methods can be costly, ineffective, and painful, highlighting the need for more efficient alternatives. SERDA's developmental prescription product aims to address these issues by providing a fast and effective means of wound debridement, which is supported by promising preclinical data.

The core of SERDA's technology lies in a specialized proteolytic enzyme that selectively digests and removes necrotic tissue and eschar from wounds. This targeted approach not only facilitates the healing process but also minimizes irritation and enhances ease of use for both patients and healthcare professionals. By focusing on high stability and low to moderate irritation potential, SERDA Therapeutics is positioned to offer a significant advancement in wound care, ultimately improving patient outcomes and reducing the burden on healthcare systems.

Netherlands

SERDA Therapeutics is a biopharmaceutical company that develops a wound debridement solution specifically designed to treat severe burn injuries and persistent ulcers such as pressure ulcers.

SERDA Therapeutics

Company Details